PDCD1LG2 and poikiloderma with neutropenia: While the mechanism by which ICI therapy induces PN has not been thoroughly discussed, it is hypothesized that PD-1 inhibitor administration may shift the immune response towards Th2-type inflammation through PD-L2 activation, contributing to the development of PN [36].